Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progression. The evolution of FVC and DLCO for 48 months remained stable with ABA therapy. Serrano-Combarro A, Abst#2173 #ACR23 @RheumNow https://t.co/QE61wzKWXi https://t.co/xd3wvMXUlA

Continued interest on CAR-T cells in systemic sclerosis! 6 mo f/up data on 3 pts who received CAR-T cell treatment - stable dz overall Skin findings improved in all 3 pts Previous finger ulcerations resolved Lung function stable in 2 pts, improved in 1 @RheumNow #ACR23 Abs#2598

#ACR23 Daily Recap - MONDAY https://t.co/PsCTB36BvR https://t.co/6cBHwm1ubY

• ACR 2023 Daily Recap - MONDAY | RheumNow

The Heart of Lupus During ACR 2023 Convergence, several abstracts were presented evaluating the prevalence of CV disease and exploring new tools to predict CV disease. The ones that caught my eye included... https://t.co/5Qk2fF3nlA #ACR23 https://t.co/Rja7K44BUf

• The Heart of Lupus | RheumNow

L16 @ #ACR23 ⭐️Can you discontinue glucocorticoids (GC) & immunosuppressive agent (IM) in stable IgG4-RD (clinically quiescent for at least 12 mo)? ➡️146 pts followed for 18 mo: 👉Group 1: withdraw GC+IM vs 👉Group 2: withdraw GC… https://t.co/j77xYm9qSN https://t.co/72IwBeEwv9

Peng et al. 146 IgG4-RD in remission on immunomodulators+GC. 18 month follow-up. Withdraw IM+GC - 52% flare. Withdraw GC + continue IM 14.2% flare. Continue both 12.2% flare. Clear message that ongoing IM is the way Abstr#L16 #ACR23 #ACRbest @RheumNow https://t.co/3CAQhyTYqq https://t.co/qr1GOSvJYg

L16 #ACR23 @RheumNow W/d of Immunosuppr and Low-dose steroid in IgG4RD Gr1: W/d GC+IM, G2: IM alone, G3: Maintain Relapse rate: G1 52%, G2 14%, G3 12% https://t.co/xe6NLVxUov

COVAD2 data: ⬆️proportion of SLE pts from lmHDI countries were on CS(73% vs 59% p=0.0002), antimalarials(81% vs 68% p=0.0002) & IS(66% vs 53%p=0.0009) vs pts from hvhHDI countries Comorbids more in younger pts from lmHDI (prob from CS use) #ACR23 ABST2269 @RheumNow @rheumarhyme https://t.co/4CLGFYG1d0

What's the long-term mainentance game plan in IgG4-RD? WInS IgG4-RD study China, n=146 IgG4-RD stable disease >12mo Withdrawing both IM+GC completely has much higher relapse rates vs at least keeping some IM IgG4-RD needs some steroid-sparing Rx ongoing #ACR23 L16 @RheumNow https://t.co/1JJpQmFTF5

L18 @ #ACR23 ⭐️Clinical Implications in Primary Sjögren's Syndrome (pSS) by Molecular classification of Salivary Glands (SGs) ➡️ transcriptomic profiling of SGs in Chinese cohort 👉 396 pSS, 87 non-pSS, & 44 early-pSS ➡️ 3 distinct sub-types: ⭐️Pacui-immune/C1… https://t.co/3ZdrghCB6F https://t.co/hZ9S3hvCzv

Withdrawing immunosuppression and steroids in IgG4-RD Maintaining immunosuppression with or without steroids associated with low relapse rate 52% of pts who withdrew steroids +immunosuppression relapsed @RheumNow #ACR23 Abs#L16 https://t.co/xJyDiCkMVD

L17 #ACR23 @RheumNow Afimetoran TLR7/8 inhib for cutaneous lupus Safety: No SAEs, mild-mod AEs, lower than PBO Nasopharyngitis & bronchitis Trough concentration consistent from D8 to 113, support 30 mg qd CLASI change; MCDI 50% Afim v 0% PB, CLASI-50 Afim 50% v 0% Inhib of IFNGS https://t.co/cKYY6rmIWE

#ACR23 Abs 2598 show data on 1st 3 CD19 CAR-T treated SSc pts. Tx well tolerated and dz stabilized off tx x 6 months. Promising, but more data needed for further evaluation. https://t.co/RAKhT6Eygn @rheumnow

L19 #ACR23 @RheumNow Hunter: TLC599 injxn for knee OA Liposomal formulation of dexamathasone sodium phosphate Improved WOMAC Pain, Fxn, and Aver Daily Pain Separation of ADP at wk 12 through wk 24 2nd injxn at wk 24 - further benefit @AusRheum https://t.co/PP7lEsclIc